Source:http://linkedlifedata.com/resource/pubmed/id/16651815
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2006-5-2
|
| pubmed:abstractText |
Stroke is the second to third leading cause of death and the main cause of severe, long-term disability in adults. However, treatment is almost reduced to fibrinolysis, a therapy useful in a low percentage of patients. Given that the immediate treatment for stroke is often unfeasible in the clinical setting, the need for new therapy strategies is imperative. After stroke, the remaining impairment in functions essential for routine activities, such as movement programming and execution, sensorimotor integration, language and other cognitive functions have a deep and life-long impact on the quality of life. An interesting point is that a slow but consistent recovery can be observed in the clinical practice over a period of weeks and months. Whereas the recovery in the first few days likely results from edema resolution and/or from reperfusion of the ischemic penumbra, a large part of the recovery afterwards is due mainly to brain plasticity, by which some regions of the brain assume the functions previously performed by the damaged areas. Neurogenesis and angiogenesis are other possible mechanisms of recovery after stroke. An understanding of the mechanisms underlying functional recovery may shed light on strategies for neurorepair, an alternative with a wide therapeutic window when compared with neuroprotective strategies.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cytidine Diphosphate Choline,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Neuroprotective Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Uptake Inhibitors
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1015-9770
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 2006 S. Karger AG, Basel.
|
| pubmed:issnType |
Print
|
| pubmed:volume |
21 Suppl 2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
54-63
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16651815-Animals,
pubmed-meshheading:16651815-Brain,
pubmed-meshheading:16651815-Cell Differentiation,
pubmed-meshheading:16651815-Cell Movement,
pubmed-meshheading:16651815-Cell Proliferation,
pubmed-meshheading:16651815-Clinical Trials as Topic,
pubmed-meshheading:16651815-Combined Modality Therapy,
pubmed-meshheading:16651815-Cytidine Diphosphate Choline,
pubmed-meshheading:16651815-Dopamine Agents,
pubmed-meshheading:16651815-Humans,
pubmed-meshheading:16651815-Neuronal Plasticity,
pubmed-meshheading:16651815-Neurons,
pubmed-meshheading:16651815-Neuroprotective Agents,
pubmed-meshheading:16651815-Regenerative Medicine,
pubmed-meshheading:16651815-Serotonin Uptake Inhibitors,
pubmed-meshheading:16651815-Stem Cell Transplantation,
pubmed-meshheading:16651815-Stem Cells,
pubmed-meshheading:16651815-Stroke
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Neurorepair versus neuroprotection in stroke.
|
| pubmed:affiliation |
Departamento de Farmacología, Facultad de Medicina, Universidad Complutense de Madrid, Spain.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|